Inactive Instrument

Analyst Reco. GEMI THER

Equities

HC Wainwright Downgrades Gemini Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $5	22-03-11	MT
SVB Leerink Downgrades Gemini Therapeutics to Market Perform from Outperform, Adjusts Price Target to $2 from $10	22-03-03	MT
HC Wainwright Adjusts Price Target on Gemini Therapeutics to $5 From $20, Reiterates Buy Rating	22-03-01	MT
Jefferies Downgrades Gemini Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $23	22-03-01	MT
SVB Leerink Adjusts Gemini Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating	22-01-24	MT
SVB Leerink Adjusts Gemini Therapeutics' Price Target to $15 from $25, Keeps Outperform Rating	21-12-20	MT
HC Wainwright Starts Gemini Therapeutics at Buy With $20 Price Target	21-12-15	MT
Stifel Adjusts Gemini Therapeutics' Price Target to $11 from $20, Maintains Buy Rating	21-11-22	MT
GEMINI THERAPEUTICS : Goldman Sachs Adjusts Gemini Therapeutics' Price Target to $18 from $20, Keeps Buy Rating	21-10-06	MT
GEMINI THERAPEUTICS : SVB Leerink Starts Gemini Therapeutics at Outperform With $25 Price Target	21-04-08	MT
GEMINI THERAPEUTICS : Jefferies Starts Gemini Therapeutics at Buy With $23 Price Target	21-03-03	MT
GEMINI THERAPEUTICS : Goldman Sachs Starts Gemini Therapeutics at Buy With $20 Price Target	21-03-02	MT
GEMI THER : Stifel Starts Gemini Therapeutics at Buy With $20 Price Target	21-02-16	MT

No results for this search